Herminia D. Rosas

Dr. Herminia D. Rosas


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2002 in Neurology
Verified
Journal Article
Closed access
PDF file
HRHerminia D. Rosas
Herminia D. Rosas
ALA. K. Liu
A. K. Liu
SHS. Hersch
S. Hersch
MGM. Glessner
M. Glessner
RFR. J. Ferrante
R. J. Ferrante
BFB. Fischl
B. Fischl
Background: Huntington’s disease (HD) is a fatal and progressive neurodegenerative disease that is accompanied by involuntary movements, cognitive dysfunction, and psychiatric symptoms. Although progressive striatal degeneration is known to occur, little is known about how the disease affects the cortex, including which cortical regions are affected, how degeneration proceeds, and the relationship of the cortical degeneration to clinical symptoms. The cortex has been difficult to study in neurodegenerative diseases primarily because of its complex folding patterns and regional variability; however, an understanding of how the cortex is affected by the disease may provide important new insights into it. Methods: Novel automated surface reconstruction and high-resolution MR images of 11 patients with HD and 13 age-matched subjects were used to obtain cortical thickness measurements. The same analyses were performed on two postmortem brains to validate these methods. Results: Regionally specific heterogeneous thinning of the cortical ribbon was found in subjects with HD. Thinning occurred early, differed among patients in different clinical stages of disease, and appeared to proceed from posterior to anterior cortical regions with disease progression. The sensorimotor region was statistically most affected. Measurements performed on MR images of autopsy brains analyzed similarly were within 0.25 mm of those obtained using traditional neuropathologic methods and were statistically indistinguishable. Conclusions: The authors propose that the cortex degenerates early in disease and that regionally selective cortical degeneration may explain the heterogeneity of clinical expression in HD. These measures might provide a sensitive prospective surrogate marker for clinical trials of neuroprotective medications.

26 February 2008 in Brain
Verified
Journal Article
Open access
PDF file
HRHerminia D. Rosas
Herminia D. Rosas
DSDavid H. Salat
David H. Salat
SLStephanie Y. Lee
Stephanie Y. Lee
AZAlexandra K. Zaleta
Alexandra K. Zaleta
VPVasanth Pappu
Vasanth Pappu
SHSteven M. Hersch
Steven M. Hersch
The clinical phenotype of Huntington's disease (HD) is far more complex and variable than depictions of it as a progressive movement disorder dominated by neostriatal pathology represent. The availability of novel neuro-imaging methods has enabled us to evaluate cerebral cortical changes in HD, which we have found to occur early and to be topographically selective. What is less clear, however, is how these changes influence the clinical expression of the disease. In this study, we used a high-resolution surface based analysis of in vivo MRI data to measure cortical thickness in 33 individuals with HD, spanning the spectrum of disease and 22 age- and sex-matched controls. We found close relationships between specific functional and cognitive measures and topologically specific cortical regions. We also found that distinct motor phenotypes were associated with discrete patterns of cortical thinning. The selective topographical associations of cortical thinning with clinical features of HD suggest that we are not simply correlating global worsening with global cortical degeneration. Our results indicate that cortical involvement contributes to important symptoms, including those that have been ascribed primarily to the striatum, and that topologically selective changes in the cortex might explain much of the clinical heterogeneity found in HD. Additionally, a significant association between regional cortical thinning and total functional capacity, currently the leading primary outcome measure used in neuroprotection trials for HD, establishes cortical MRI morphometry as a potential biomarker of disease progression.

27 May 2003 in Neurology
Verified
Journal Article
Closed access
PDF file
HRHerminia D. Rosas
Herminia D. Rosas
WKW. J. Koroshetz
W. J. Koroshetz
YCY. I. Chen
Y. I. Chen
CSC. Skeuse
C. Skeuse
MVM. Vangel
M. Vangel
JGJ. M. Goldstein
J. M. Goldstein
Background: Most clinical symptoms of Huntington disease (HD) have been attributed to striatal degeneration, but extrastriatal degeneration may play an important role in the clinical symptoms because postmortem studies demonstrate that almost all brain structures atrophy. Objective: To fully characterize the morphometric changes that occur in vivo in HD. Methods: High-resolution 1.5 mm T1-weighted coronal scans were acquired from 18 individuals in early to mid-stages of HD and 18 healthy age-matched controls. Cortical and subcortical gray and white matter were segmented using a semiautomated intensity contour-mapping algorithm. General linear models for correlated data of the volumes of brain regions were used to compare groups, controlling for age, education, handedness, sex, and total brain volumes. Results: Subjects with HD had significant volume reductions in almost all brain structures, including total cerebrum, total white matter, cerebral cortex, caudate, putamen, globus pallidus, amygdala, hippocampus, brainstem, and cerebellum. Conclusions: Widespread degeneration occurs in early to mid-stages of HD, may explain some of the clinical heterogeneity, and may impact future clinical trials.

5 June 2006 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
HRHerminia D. Rosas
Herminia D. Rosas
DTDavid S. Tuch
David S. Tuch
NHNathanael D. Hevelone
Nathanael D. Hevelone
AZAlexandra K. Zaleta
Alexandra K. Zaleta
MVMark Vangel
Mark Vangel
DSDavid H. Salat
David H. Salat

13 September 2005 in Neurology
Verified
Journal Article
Closed access
PDF file
HRHerminia D. Rosas
Herminia D. Rosas
NHN. D. Hevelone
N. D. Hevelone
AZA. K. Zaleta
A. K. Zaleta
DGD. N. Greve
D. N. Greve
DSD. H. Salat
D. H. Salat
BFB. Fischl
B. Fischl
The authors studied presymptomatic individuals with the Huntington disease (HD) mutation to determine whether cortical thinning was present. They found thinning that was regionally selective, semi-independent of striatal volume loss, and correlated with cognitive performance. Early, extensive cortical involvement occurs during the preclinical stages of HD.

1 February 2010 in NeuroImage
Verified
Journal Article
Closed access
HRHerminia D. Rosas
Herminia D. Rosas
SLStephanie Y. Lee
Stephanie Y. Lee
ABAlexander C. Bender
Alexander C. Bender
AZAlexandra K. Zaleta
Alexandra K. Zaleta
MVMark Vangel
Mark Vangel
SHSteven M. Hersch
Steven M. Hersch